Cutting back the thickets of Biosimilars

The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act (BPCIA) in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amgen and Daiichi Sankyo ink biosimilar agreement

15 July 2016 Biotechnology company Amgen and Japan-based Daiichi Sankyo have agreed a deal that will allow for the commercialisation of nine biosimilars in Japan.

Americas

25 October 2017 Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.

More on this story

Americas

Amgen and Daiichi Sankyo ink biosimilar agreement

15 July 2016 Biotechnology company Amgen and Japan-based Daiichi Sankyo have agreed a deal that will allow for the commercialisation of nine biosimilars in Japan.

Americas

More on this story

Americas

Amgen and Daiichi Sankyo ink biosimilar agreement

15 July 2016 Biotechnology company Amgen and Japan-based Daiichi Sankyo have agreed a deal that will allow for the commercialisation of nine biosimilars in Japan.

Americas